No evidence that CAR T cell therapy causes secondary cancers, large study shows
Within a large group of more than 700 patients treated with CAR T cell therapy, researchers found no evidence that the ...
technologynetworks1 天
Study Finds No Evidence CAR T-Cell Therapy Causes Secondary Cancers
A study of 783 patients treated with CAR T cell therapy found no evidence that the therapy itself caused secondary cancers.
CAR-T cells can arm bystander T cells with CAR molecules in tumor microenvironment
Engineered immune cells called CAR-T cells are used in the treatment of cancer. Researchers from Uppsala University have now ...
Viral protein Nef enables a step toward off-the-shelf CAR T cell therapy for cancer
CAR T cell therapy is one of the most promising new cancer treatments to emerge in recent years. It involves removing a ...
The Scientist2 天
Inducible CAR T Cells Target Solid Tumors Better
Researchers at Cellectis leveraged gene editing to create a CAR T cell that acts in an IF/THEN system. Traditional methods to develop CAR T cells that use the patient’s cells introduce challenges ...
The Daily Pennsylvanian13 天
Penn Medicine leads cancer treatment breakthroughs in CAR T-cell therapy
Penn Medicine is one of the first institutions to develop FDA-approved CAR T-cell therapies. This therapy is currently ...
Upstate cancer survivor celebrates recovery with innovative CAR T-cell treatment
On this World Cancer Day, Chris Vogelsang, a cancer survivor from upstate New York, is celebrating his recovery thanks to a ...
Cure Today13 天
Understanding the Challenges of CAR T-Cell Therapy Treatment in R/R NHL
Yescarta continued to demonstrate durable responses after a median follow-up of more than five years in patients with R/R ...
FierceBiotech6 天
Cargo offloads CAR-T along with half of its workforce in wake of low efficacy, toxic side ...
The drug in question, called firicabtagene autoleucel or firi-cel, is an autologous CD22 CAR-T cell therapy that had been ...
Targeted Oncology13 天
First Dose of CD38-Targeting CAR T-Cell Therapy Administered in AML
The first patient with relapsed/refractory acute myeloid leukemia has received KJ-C2320, an allogeneic CAR T-cell therapy ...
STAT5 天
CAR-T cells can arm other immune cells with engineered proteins to fight cancer, study says
it’s not yet clear how sharing CARs between T cells might impact CAR-T therapy efficacy or influence the design of future synthetic receptors, experts told STAT. However, the work does reveal ...
Targeted Oncology9 天
Novel CAR T-Cell Therapy GCC19CART Active in Refractory mCRC
Preliminary findings from the phase 1 trial showed that GCC19CART, a novel CAR T-cell therapy, demonstrated clinical ...